360b / Shutterstock.com
Pfizer has had a patent application for tofacitinib, which is marketed as Xeljanz and Jakvinus, rejected by the Indian Patent Office (IPO) for the second time.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Pfizer; Indian Patent Office; IPAB; tofacitinib; Xeljanz; Jakvinus